Becker Ventures
2
15M
2
- Areas of investment
Summary
The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Grosse Pointe Park.
Among the most successful fund investment fields, there are Medical, Biotechnology. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight AltheRx Pharmaceuticals.
The high activity for fund was in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Becker Ventures, startups are often financed by Longitude Capital. The meaningful sponsors for the fund in investment in the same round are Samsara BioCapital, Longitude Capital, Fountain Healthcare Partners.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Investments by industry
- Biotechnology (2)
- Health Care (2)
- Therapeutics (1)
- Medical (1)
- Medical Device (1)
- Investments by region
-
- United States (2)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Velicept Therapeutics | 16 Oct 2018 | Biotechnology, Health Care, Medical, Therapeutics | Early Stage Venture | 15M | United States, Pennsylvania |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.